Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: J Pediatr Surg. 2017 Nov 14;53(2):306–309. doi: 10.1016/j.jpedsurg.2017.11.024

Table 1.

Patient, disease, and treatment characteristics

Pathology Sex Median age at diagnosis (years) Urine cytology Median size in the greatest dimension (no. available) Treatment Median follow-up (months)
Urothelial papilloma (n=1) 1 male 21.4 All negative 1.2 cm (n = 1)

  • Transurethral complete excision

  • No chemotherapy

 5.6
PUNLMP (n=6) 5 males
1 female		 19.2 All negative 0.9 cm (n = 5)

  • Transurethral complete excision

  • No chemotherapy

 30.5
Low-grade non-invasive urothelial carcinoma (n=22) 14 males
8 females		 21.3 2 (10%) atypical cells 2.2 cm (n = 16)

  • Transurethral complete excision

  • 2 intravesicular mitomycin

  • 2 intravesicular BCG

  • 1 interferon

 28.3
High-grade non-invasive urothelial carcinoma (n=2) 1 male
1 female		 23.3 1 (50%) atypical cells Not recorded

  • Transurethral complete excision

  • No chemotherapy

 78.8
Invasive carcinoma (n=3) 1 male
2 females		 18.5 2 (100%) malignant cells 5.4 cm (n = 3)

  • 2 Laparotomy/partial cystectomy

  • 1 adjuvant chemotherapy

  • 1 chemotherapy alone

 22.7
All cases (n=34) 22 males
12 females		 21.1 5 (17%) abnormal 2.0 cm (n = 25) NA 25.1

BCG= Bacillus Calmette-Guerin; NA= not applicable; PUNLMP= papillary urothelial neoplasm of low malignant potential.